Steatosis Dose Not Affect Diagnostic Performance of Acoustic Radiation Force Impulse in Nonalcoholic Fatty Liver Disease
Kang YW, Baek YH, Lee JH, Roh YH, Kwon HJ, Moon SY, Son MK and Jeong JS
Published on: 2023-01-23
Abstract
Aim: This study aimed to compare the diagnostic performance of non-invasive tests in predicting advanced fibrosis in patients with nonalcoholic fatty liver (NAFLD) and examine whether the accuracy of each diagnostic test was maintained according to the severity of steatosis or obesity and increased NAFLD activity score (NAS).
Materials and Methods: We retrospectively enrolled 132 patients with NAFLD using ultrasonography. The anthropometric data of the patients were collected on the day of admission, and blood tests, acoustic radiation force impulse (ARFI) imaging, and biopsy were performed the following day. Non-invasive diagnostic tests were evaluated for each subgroup according to the degree of steatosis, obesity, and nonalcoholic steatohepatitis.
Results: Acoustic radiation force impulse (ARFI) showed the highest diagnostic value among the various non-invasive tests. The area under the receiver operating characteristic curve (AUROC) values of ARFI, Aspartate aminotransferase to Platelet Ratio Index (APRI), fibrosis-4 index (FIB-4), and NAFLD fibrosis score (NFS) in the morbidly obese subgroup were 0.808, 0.793, 0.742, and 0.672, respectively. In the group having severe steatosis or NAS, the AUROC values of ARFI, APRI, FIB-4, and NFS were 0.716, 0.629, 0.669, and 0.617, for severe steatosis and 0.801, 0.723, 0.756, and 0.693, respectively, for NAS. ARFI was the only statistically significant test in patients with severe steatosis.
Conclusion: The ARFI remained unaffected by various factors, retaining its diagnostic performance. Therefore, we suggest that ARFI imaging is a good diagnostic test for screening advanced fibrosis in patients with NAFLD.
Keywords
Hepatic fibrosis; Nonalcoholic fatty liver disease; Acoustic radiation force impulse; Non-invasive testIntroduction
Nonalcoholic fatty liver disease (NAFLD) affects approximately one-fourth of the general population worldwide. [1-2] In Asian countries, recent reports have revealed an increasing trend in the prevalence of NAFLD; in Korea, the prevalence of NAFLD has been estimated to range from 21% to 44%, with a median of 30% in the general population. [3] NAFLD includes a histologic spectrum ranging from simple steatosis to nonalcoholic steatohepatitis (NASH) to advanced fibrosis and cirrhosis. Recent studies have demonstrated that advanced fibrosis and cirrhosis are the most important predictors of mortality and the development of liver-related complications. [4-5] Therefore, it is important to identify advanced fibrosis and cirrhosis within the spectrum of NAFLD in all patients. Traditionally, the gold standard for diagnosing liver fibrosis in patients with NAFLD is liver biopsy. [6] However, liver biopsy is an invasive procedure and is accompanied by not only minor complications, such as pain (20%), but also major complications, such as hemobilia, abdominal bleeding (0.5%), and death (0.009–0.12%). [7-9] Other major drawbacks of liver biopsy are sampling error and inter- and intra-observer variability. [10-11] Recently, many studies have been conducted to evaluate liver fibrosis using non-invasive tests to minimize liver biopsy in screening liver fibrosis. In various guidelines, the fibrosis-4 index (FIB-4), NAFLD fibrosis score (NFS), transient elastography (TE), and acoustic radiation force impulse (ARFI) have been proposed as algorithms for screening for liver fibrosis and identifying patients who require liver biopsy. [3, 12-15] Therefore, in this study, we attempted to comparatively analyze the diagnostic performance of ARFI with those of other non-invasive tests for advanced fibrosis and to evaluate differences in diagnostic performance according to the presence or absence of morbid obesity, severe steatosis, and inflammation that may be associated with NAFLD.
Methods
Study Population
From January 2017 to September 2022, 132 patients who were clinically suspected of having NAFLD and underwent biopsy at Dong-A University Hospital were retrospectively enrolled. The study’s inclusion criteria were as follows: (i) bright liver echogenicity observed on ultrasonography and (ii) an unexplainably high level of alanine transaminase (ALT) that was above the upper reference level. Patients with the following conditions were excluded from this study: (i) viral hepatitis (e.g., hepatitis B or C), (ii) autoimmune hepatitis or primary biliary cholangitis, and (iii) excessive alcohol intake (>30 g/day for male patients and >20 g/day for female patients).
Serologic Biomarkers
All patient examinations were performed after hospitalization, and anthropometric data that were collected on the day of admission were used. Blood samples, liver biopsies, and ARFI imaging were performed on the same day and after fasting for 12 h. Blood tests included assays for aspartate aminotransferase (AST), ALT, alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT) levels, and platelet count, as well as fasting glucose, albumin, lipid, and HbA1c levels. Normal reference ranges were defined as AST: 0–40 U/L, ALT: 0–41 U/L, ALP: 40–129 U/L, GGT: 0–60 U/L, platelet count: 150–450 109/L, fasting glucose: 74–100 mg/dL, Albumin: 3.4–5.4 g/dL, total cholesterol: 0–200 mg/dL, low-density lipoprotein cholesterol (LDL-C): 0–100 mg/dL, high-density lipoprotein cholesterol (HDL-C): 40–60 mg/dL, triglyceride: 0–200 mg/dl, and HbA1C: 5.7–6.4%.
The AST to Platelet Ratio Index (APRI) was calculated using the following formula:
![]()
FIB-4 was calculated using the following formula:
![]()
NFS was calculated based on age, body mass index (BMI), impaired fasting glucose (IFG) or diabetes, AST/ALT, platelet count, and albumin levels. NFS was calculated using the following formula:
Acoustic Radiation Force Impulse Imaging
ARFI imaging (Philips EPIQ7 ultrasound system, Supersonic Imagine S.A., France) was performed by two experienced radiologists, who were blinded to the clinical and biochemical data, using Virtual Touch tissue quantification software to obtain liver stiffness measurements (LSMs). Prior to ARFI, the gross morphologies of the liver and spleen were examined using conventional ultrasonography. Using real-time B-mode imaging, a 10×5-mm region of interest cursor was placed on the hepatic parenchyma at least 3 cm below the Glisson’s capsule, in an area that did not contain any vessels or focal liver lesions. [16] The liver stiffness was measured in the right hepatic lobe, which was accessed through intercostal space between the 9th and 10th ribs. We collected 10 valid measurements from all the patients. The median value of a series of shear wave velocities was regarded as the liver stiffness and was expressed in meters per second (m/s).
Liver Histology
Liver biopsy specimens were fixed in 4% buffered formalin and embedded in paraffin. Two micrometer-thick sections were stained with hematoxylin, eosin, and Masson’s trichrome. All liver biopsy specimens were assessed and scored by a pathologist with at least 20 years of experience in liver pathology, who was also experienced in liver histology. Liver pathology results were assessed using the NASH Clinical Research Network (CRN) staging system. The NASH CRN system describes the NAFLD activity score (NAS), which is a composite score of steatosis, lobular inflammation, cytological ballooning, and fibrosis. A NAS of 5 or higher was defined as NASH. Steatosis was scored using the following criteria: <5% = 0, 5~33% = 1, 33~66% = 2, and >66% =3. Fibrosis was scored using the following criteria: no fibrosis = F0, mild and moderate zone 3 periarticular fibrosis or portal/periportal fibrosis = F1, zone 3 perisinusoidal and portal/periportal fibrosis = F2, bridging fibrosis = F3, and cirrhosis = F4. Minimal to mild steatosis was defined as less than 33%, less than 66% was defined as moderate, while greater than 66% was defined as severe steatosis. F2 or higher was defined as significant fibrosis, and F3 or higher was defined as advanced fibrosis.
Statistical Analysis
Statistical analysis was performed using IBM SPSS Statistics version 22.0 (IBM Corp., Armonk, NY, USA) and MedCalc Software for Windows version 17.1 (MedCalc Software Ltd., 2022, 0stend Belgium). Continuous variables were expressed as mean values and standard deviations or median values and interquartile ranges. The diagnostic performance of ARFI, APRI, FIB-4, and NFS were assessed by calculating the area under the receiver operating characteristic curve (AUROC) values and 95% confidence intervals (CI). For each test, the best cut-off value was associated with the Youden index. The AUROC values of the ARFI, APRI, FIB-4, and NFS for advanced fibrosis were compared using the DeLong test. P-values less than 0.05 were considered statistically significant.
Results
Baseline Clinical and Histological Characteristics of The Population
From January 2017 to September 2022, 132 patients with a clinical suspicion of NAFLD who underwent liver biopsy at Dong-A University Hospital, were retrospectively analyzed. The baseline demographic and biochemical characteristics and histological data of the study population are summarized in (Table 1). Of the 132 patients, 68 (51.5%) were male and 64 (48.5%) were female. Furthermore, 72 (54.5%) patients had hypertension, 31 (23.5%) had IFG, and 59 (44.7%) had diabetes. A BMI of <23 kg/m2 was defined as non-obesity, and a BMI of ≥30 kg/m2 was defined as morbid obesity in the 2020 Korean Society for the Study of Obesity guidelines. [17] The mean BMI was 29.8 kg/m2; only 3.8% of patients in this study were not obese, while 42.4% were morbidly obese. Thirty (22.7%) patients had advanced fibrosis, and seven (5.3%) patients had cirrhosis. FForty-four patients had moderate steatosis, and 50 patients (37.9%) had severe steatosis. Regarding NAS, 84 of the participants (63.6%) had NASH.
Table 1: Baseline characteristics of the study population.
|
|
Total (n=132) |
|
|
Demographic |
||
|
Age at biopsy, y, mean ± SD |
|
45.29 (± 14.25) |
|
Male, n (%) |
|
68 (51.5%) |
|
Female, n (%) |
|
64 (48.5%) |
|
BMI, kg/m2, mean ± SD |
|
29.81 (± 4.38) |
|
BMI ≥ 3 |
|
56 (42.4%) |
|
Impaired fasting glucose, n (%) |
|
31 (23.5%) |
|
Diabetes, n (%) |
|
59 (44.7%) |
|
Hypertension, n (%) |
|
72 (54.5%) |
|
Biochemical profile (median, IQR) |
||
|
AST, U/L |
|
48, (14, 345) |
|
ALT, U/L |
|
47 (9, 451) |
|
Platelet count, 103/uL |
|
242 (114-642) |
|
Albumin, g/dL |
|
4.4 (3.2-5.3) |
|
Fasting glucose, mg/dL |
|
108 (68-333) |
|
Triglyceride, md/dL |
|
140 (58 -726) |
|
HDL, md/dL |
|
47 (31-61) |
|
LDL, md/dL |
|
118 (36-211) |
|
Histology |
||
|
Steatosis, n (%) |
0 |
5 (3.8%) |
|
|
1 |
33 (25.0%) |
|
|
2 |
44 (33.3%) |
|
|
3 |
50 (37.9%) |
|
Lobular inflammation, n (%) |
0 |
21 (15.9%) |
|
|
1 |
31 (23.5%) |
|
|
2 |
50 (37.9%) |
|
|
3 |
30 (22.7%) |
|
Ballooning, n (%) |
0 |
44 (33.3%) |
|
|
1 |
54 (40.9%) |
|
|
2 |
34 (25.8%) |
|
Fibrosis, n (%) |
0 |
48 (36.4%) |
|
|
1 |
41 (31.1%) |
|
|
2 |
13 (9.8%) |
|
|
3 |
23 (17.4%) |
|
|
4 |
7 (5.3%) |
|
NAFLD activity score, n (%) |
not NASH (NAS ≤2) |
30 (22.7%) |
|
|
Borderline NASH |
18 (13.6%) |
|
|
Definite NASH (NAS ≥5) |
84 (63.6%) |
AST: aspartate aminotransferase, ALT: alanine aminotransferase, HDL: high density lipoprotein, LDL: low density lipoprotein, NAFLD: non-alcoholic fatty liver disease, NASH: non-alcoholic steatohepatitis.
Diagnostic performance of ARFI, APRI, FIB-4, and NFS for advanced fibrosis
Among the non-invasive fibrosis tests, the diagnostic performances of ARFI, APRI, FIB-4, and NFS were 0.841 (95% CI, 0.767 to 0.898); 0.811 (95% CI, 0.733 to 0.874); 0.769 (95% CI, 0.688 to 0.838); and 0.694 (95% CI, 0.608 to 0.771), respectively. The cut-off values suggested in the AUROC analysis of our study were >1.25, >0.637, >1.75, and >-0.3 for ARFI, APRI, FIB-4, and NFS, respectively (Table 2).
Table 2: Diagnostic performance of ARFI, APRI, FIB-4 and NFS for advanced fibrosis.
|
|
AUROC (95% CI) |
Cut off |
Sensitivity (%) |
Specificity (%) |
PPV (%) |
NPV (%) |
P value |
|
ARFI |
0.841 (0.767-0.898) |
>1.25 |
80 |
71.6 |
54.7 |
89.3 |
0 |
|
APRI |
0.811 (0.733-0.874) |
>0.637 |
73.3 |
78.4 |
59.3 |
87.3 |
0 |
|
FIB-4 |
0.769 (0.688-0.838) |
>1.75 |
63.7 |
86.3 |
66.4 |
84.6 |
0 |
|
NFS |
0.694 (0.608-0.771) |
>-0.3 |
60 |
81.4 |
58 |
82.6 |
0.001 |
ARFI: acoustic radiation force impulse, APRI: aspartate aminotransferase-to-platelet ratio index, FIB-4: fibrosis-4 index, NFS: non-alcoholic fatty liver disease fibrosis score, PPV: positive predictive value, NPV: negative predictive value.
Summarizes the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of ARFI, APRI, FIB-4, and NFS according to the cut-off values. The AUROC value of ARFI was the best compared with those of the other tests, and its sensitivity and NPV were also the best compared with those of other non-invasive tests. A comparative analysis was conducted to determine whether the ARFI was statistically superior to the APRI, FIB-4, and NFS. Statistically, diagnostic performance of ARFI was not significantly different from APRI and FIB-4 but showed significant superiority over NFS (p=0.0117) (Figure 1).

|
|
P value |
|
ARFI ~ APRI |
0.5823 |
|
ARFI ~ FIB-4 |
0.1872 |
|
ARFI ~ NFS |
0.0117 |
Figure 1: Comparison of Diagnostic predictive value between each non-invasive fibrosis tests.
Diagnostic predictive performance of ARFI, APRI, FIB-4, and NFS according to subgroups, such as obesity, steatosis, and NASH.
In the analysis of diagnostic performance according to the degree of obesity, the AUROC of ARFI was 0.808 (95% CI, 0.681 to 0.901, p=0.000) in the morbidly obese group, which indicated superior diagnostic performance compared with other non-invasive tests (Figure 2-1).

|
|
AUROC |
95% CI |
P value |
|
ARFI |
0.837 |
0.704-0.971 |
0 |
|
APRI |
0.823 |
0.700-0.946 |
0 |
|
FIB-4 |
0.785 |
0.643-0.927 |
0.001 |
|
NFS |
0.733 |
0.573-0.894 |
0.009 |
Figure 2: Diagnostic predictive value of each non-invasive tests according to subgroups.

|
|
AUROC |
95% CI |
P value |
|
ARFI |
0.808 |
0.687-0.929 |
0 |
|
APRI |
0.793 |
0.672-0.915 |
0.001 |
|
FIB-4 |
0.742 |
0.565-0.920 |
0.006 |
|
NFS |
0.672 |
0.488-0.856 |
0.051 |
Figure 2-1: Diagnostic predictive value of each test with or without morbid obesity.
A comparative analysis of AUROC between each non-invasive test was conducted to determine whether ARFI was statistically superior to APRI, FIB-4, and NFS in the morbidly obese group. The results did not show statistical significance for ARFI over APRI, FIB-4, or NFS. (p=0.8449, p=0.4815, p=0.1611). The comparison of diagnostic performance of non-invasive tests for advanced fibrosis in the histological steatosis subgroups is shown in Figure (2-2).

|
|
AUROC |
95% CI |
P value |
|
ARFI |
0.937 |
0.856-1.000 |
0.005 |
|
APRI |
0.985 |
0.949-1.000 |
0.002 |
|
FIB-4 |
0.754 |
0.381-1.000 |
0.101 |
|
NFS |
0.676 |
0.277-1.000 |
0.254 |

|
|
AUROC |
95% CI |
P value |
|
ARFI |
0.926 |
0.850-1.000 |
0 |
|
APRI |
0.842 |
0.716-0.969 |
0.001 |
|
FIB-4 |
0.94 |
0.874-1.000 |
0 |
|
NFS |
0.862 |
0.741-0.983 |
0 |

|
|
AUROC |
95% CI |
P value |
|
ARFI |
0.716 |
0.558-0.874 |
0.019 |
|
APRI |
0.629 |
0.453-0.805 |
0.16 |
|
FIB-4 |
0.669 |
0.491-0.846 |
0.066 |
|
NFS |
0.617 |
0.441-0.793 |
0.202 |
Figure 2-2: Diagnostic predictive value of each test according to the steatosis severity.
In the severe steatosis group, the AUROC of ARFI, APRI, FIB-4, and NFS were 0.716 (95% CI, 0.558 to 0.874); 0.629 (95% CI, 0.453 to 0.805); 0.669 (95% CI, 0.491 to 0.846); and 0.617 (95% CI, 0.441 to 0.793), respectively. In the AUROC analysis of APRI, FIB-4, and NFS (except for ARFI), the 95% CI included a value of 0.5 or less, and the p-value was higher than 0.05; therefore, the AUROC was not statistically significant in APRI, FIB-4, and NFS. Regardless of the degree of steatosis, only ARFI imaging maintained a constant statistical significance. When subgroups were divided using NAS, the AUROC values of ARFI, APRI, FIB-4, and NFS in the NASH group were 0.801 (95% CI, 0.700–0.901); 0.723 (95% CI, 0.609–0.838); 0.756 (95% CI, 0.638–0.875); and 0.693 (95% CI, 0.566–0.820), respectively (Figure 2-3). The diagnostic predictive performance of the ARFI was the best in this subgroup. In the NASH subgroup, the AUROC was compared and analyzed between non-invasive tests to determine whether the diagnostic predictive value of ARFI was statistically superior to those of other tests. The results showed that ARFI was not statistically superior to APRI, FIB-4, or NFS (p=0.2556, p=0.4750, p=0.1078, respectively).

|
AUROC |
95% CI |
P value |
|
|
ARFI |
0.962 |
0.891-1.000 |
0.028 |
|
APRI |
0.799 |
0.507-1.000 |
0.156 |
|
FIB-4 |
0.848 |
0.622-1.000 |
0.099 |
|
NFS |
0.815 |
0.572-1.000 |
0.135 |

|
|
AUROC |
95% CI |
P value |
|
ARFI |
0.801 |
0.700-0.901 |
0 |
|
APRI |
0.723 |
0.609-0.838 |
0.001 |
|
FIB-4 |
0.756 |
0.638-0.875 |
0 |
|
NFS |
0.693 |
0.566-0.820 |
0.004 |
Figure 3-3: Diagnostic predictive value of each test with or without NASH.
Discussion
Accurate assessment of advanced fibrosis is important for decision-making during treatment and for predicting overall survival, liver transplantation, and liver-related complications. [18-19] Although liver biopsy is the standard diagnostic tool for assessing fibrosis, many recent studies have been conducted to evaluate liver fibrosis using non-invasive tests to minimize the risk associated with performing liver biopsy. [20-21] Based on these studies, diagnostic algorithms, including non-invasive tests, have been presented in various guidelines. [3,13,14,23] In our study, among non-invasive tests that predict fibrosis, APRI, FIB-4, and NFS, were used as serological fibrosis markers, and ARFI imaging was used as an imaging method. APRI was initially established for patients with hepatitis C virus (HCV) or human immunodeficiency virus/HCV coinfection. [24] In many cases, thresholds were modified from the results of the tests obtained in patients with chronic HCV and adapted for NAFLD-related advanced fibrosis. In the analysis of 315 patients with NAFLD at Seoul National University, the AUROC value of APRI was reported as 0.830 (95% CI, 0.770–0.890; cut-off=0.562; PPV=38.1%, NPV=94.9%; p=0.374). [25] In our study, results of the AUROC values of APRI were similar to those of previous studies. APRI yielded a high NPV but had a poor PPV, suggesting that APRI can be used to exclude patients who do not have advanced fibrosis, thereby avoiding unnecessary liver biopsies. However, major drawbacks include reduced accuracy for detecting early stages of fibrosis and a high proportion of patients with variability in results due to changes in ALT levels. [26-27]. FIB-4 is a widely validated non-invasive test, and owing to the use of a simple testing method, it is regarded as a useful test for identifying patients with advanced fibrosis. [28-29] FIB-4 is known to have good diagnostic performance, with an AUROC of 0.8 or higher in several studies that evaluated its usefulness in predicting advanced fibrosis. [27,30] However, FIB-4 has reduced specificity in older patients, and new thresholds for patients aged ≥65 years have been proposed. [31] In our study; the AUROC value was 0.769, showing a relatively low diagnostic performance. FIB-4 varies greatly in value depending on age and the influence of platelet count, because the FIB-4 formula includes age, platelet count, AST, and ALT. When analyzing the age of patients included in our study, the average age was 45 years. 32.6% of the patients were younger than 35 years or older than 65 years of age. In other studies, patients with normal platelet counts were included and the age of the participants was limited to the range that could be evaluated; however, additional reasons for the low diagnostic performance in our study are needed. In many published studies, the AUROC value was 0.8 or higher, which indicated a good diagnostic performance [32-34].
In our study, NFS had a relatively low AUROC value and showed a fair diagnostic predictive performance. NFS varies in value depending on the presence or absence of IFG and DM [35]. In the aforementioned studies, IFG or diabetes accounted for less than half of all patients. In our study, patients with IFG and diabetes accounted for 68.2% of the participants. The reason the AUROC value for NFS was low in our study may be because of the high proportion of patients with IFG and diabetes. Moreover, the discrepancy in the diagnostic performance of NFS between studies might be attributed to the difference in the prevalence of obesity between Asian and Caucasian populations with NAFLD [36-37]. In addition, studies have shown that sex, waist circumference, serum LDL-C, glomerular filtration rate, smoking, and exercise are factors that affect NFS [35]. The fact that the diagnosis of NFS was influenced by several factors suggests that its diagnostic value might vary depending on the characteristics of the population. Although ARFI was used in our study, TE is more commonly used to screen for liver fibrosis [38-39]. In a large study (n=246 patients with NAFLD), TE had an AUROC of 0.93 for detecting advanced fibrosis [40]. Other smaller studies in Caucasian and Japanese patients with NAFLD also reported similarly high accuracy of TE in detecting advanced fibrosis [41-44]. However, in overweight and obese patients, 24-35% of the measurements were considered unreliable. [45-49] This technique is influenced by BMI, metabolic syndrome, and sex [50]. Although obesity is one of the limiting factors, this has been partially solved by the development of a large XL probe, designed to assess the liver at a depth of more than 2.5 cm from the skin [51-52].
However, the validity and cut-off value for this probe in the assessment of fibrosis has not been established. Compared with TE, ARFI has the great advantage of being included in standard ultrasound equipment; therefore, it can be used to complement conventional B-mode whole liver evaluation, with higher reproducibility in obese and ascitic patients [53]. Recent data suggest that ARFI may have a diagnostic accuracy comparable to that of TE [52, 54]. In a meta-analysis of four initial studies of patients with chronic liver disease, which included 77 patients with NAFLD, ARFI had an AUROC of 0.86 for the diagnosis of advanced fibrosis [55]. In a more recent large study of 172 patients with biopsy-diagnosed NAFLD, the AUROC was 0.90 for detecting advanced fibrosis. [56] Compared with TE, ARFI has similar accuracy but lower rates of measurement failures [55, 57-59]. However, ARFI has limitations, including the fact that it requires the operator to define the region of interest and obtain a series of LSMs. The values may vary depending on the skill level of the operator. Additionally, the good diagnostic performance of ARFI has been reported in few studies, and each study had a different cut-off; therefore, additional data on its optimal cut-off value and quality criteria are needed [60]. We analyzed the diagnostic performance of ARFI compared with other non-invasive test and the AUROC of ARFI was 0.841, which is consistent with those of other published studies. Previous studies have shown that the degree of obesity, steatosis, or inflammation reduce the diagnostic accuracy of the non-invasive tests [61-64]. We classified patients with NAFLD into subgroups according to obesity, steatosis, and NASH; no previous study has compared and analyzed the diagnostic performance of non-invasive tests for these subgroups. In our study, the proportion of patients with morbid obesity, severe steatosis, and NASH was 42.4%, 37.9%, and 63.6%, respectively. Our subgroup tended to have poor diagnostic accuracy for all non-invasive tests, and ARFI showed consistently showed better diagnostic performance than the other non-invasive tests, and was only statistically significant in patients with severe steatosis. Moreover, ARFI maintained a good diagnostic performance while maintaining statistical significance with a p-value < 0.05 in each subgroup analysis. This study has some limitations. First, there may be antecedent bias because the study was performed at a single institution and patients who had a liver biopsy were included as needed. Future studies may require larger multicenter settings. Second, we did not perform TE, which is the most widely used test for LSM; hence, we could not directly compare TE with ARFI. In addition, the LSM cut-off determined by ARFI is difficult to use generally for classifying fibrotic stages due to the narrow range of LSM values. Third, we did not analyze various risk factors that may have influenced the discordant results between the non-invasive tests and histological data. NAFLD is a heterogeneous disease that can be caused by a variety of factors and has various comorbid metabolic diseases; therefore, it is very difficult to find a suitable non-invasive test considering all influencing factors. NAFLD should be tested to show persistent diagnostic performance, regardless of various comorbid diseases or confounding factors. In this study, ARFI did not show statistical significance compared with APRI, FIB-4, and NFS when comparing the diagnostic performance of all subgroups but maintained good diagnostic values in various patient groups. In conclusion, our findings demonstrated the usefulness of ARFI as a screening test in patients with NAFLD, regardless of morbid obesity, NASH or severe steatosis.
Conclusion
Fibrosis, although important in the prognosis of NAFLD, is difficult to evaluate without a biopsy; its evaluation is further complicated by morbid obesity, severe steatosis, and inflammation. ARFI remained unaffected by various factors, retaining its diagnostic performance. Therefore, we suggest that ARFI imaging is a good diagnostic test for screening advanced fibrosis in patients with NAFLD.
Acknowledgments
No financial support.
Conflicts of Interest
None.
References
- Younossi ZM, Stepanova M, Younossi Y. Epidemiology of chronic liver diseases in the USA in the past three decades. Gut 2020; 69: 564-568.
- Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M, et al. Global epidemiology of non-alcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64: 73-84.
- Kang SH, Lee HW, Yoo JJ. KASL clinical practice guidelines: Management of non-alcoholic fatty liver disease. Clin Mol Hepatol 2021; 27: 363.
- Dulai PS, Singh S, Patel J. Increased risk of mortality by fibrosis stage in non-alcoholic fatty liver disease: Systematic review and meta-analysis. Hepatology 2017; 65: 1557-1565.
- Loomba R, Wong R, Fraysse J. Non-alcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real-world analysis of Medicare data. Aliment Pharmacol Ther 2020; 51: 1149-1159.
- Afdhal NH, Nunes D. Evaluation of liver fibrosis: a concise review. Am J Gastroenterol 2004; 99: 1160-1174.
- West J, Card TR. Reduced mortality rates following elective percutaneous liver biopsies. Gastroenterology 2010; 139: 1230-1237.
- Terjung B, Lemnitzer I, Dumoulin FL. Bleeding complications after percutaneous liver biopsy. An analysis of risk factors. Digestion 2003; 67: 138-145.
- Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology 2000; 32: 477-481.
- Ratziu V, Charlotte F, Heurtier A. Sampling Variability of Liver Biopsy in Non-alcoholic Fatty Liver Disease. Gastroenterology 2005; 128: 1898-1906.
- Merriman RB, Ferrell LD, Patti MG. Correlation of paired liver biopsies in morbidly obese patients with suspected non-alcoholic fatty liver disease. Hepatology 2006; 44: 874-880.
- Ando Y, Jou JH. Non-alcoholic fatty liver disease and recent guideline updates. Clin Liver Dis 2021; 17: 23-28.
- European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016; 64: 1388-1402.
- Chalasani N, Younossi Z, Lavine JE. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55: 2005-2023.
- Castera L, Chan H, Arrese M. for the Clinical Practice Guideline Panel. EASL-ALEH clinical practice guidelines: noninvasive tests for evaluation of liver disease severity and prognosis. J Hepatol 2015; 63: 237-264.
- Roulot D, Czernichow S, Le Clésiau H, Costes JL, Vergnaud AC, Beaugrand M, et al. Liver stiffness values in apparently healthy subjects: influence of gender and metabolic syndrome. J Hepatol 2008; 48: 606-613.
- Kim BY, Kang SM, Kang JH. 2020 Korean Society for the Study of Obesity Guidelines for the Management of Obesity in Korea. J Obes Metab Syndr. 2021; 30: 81-92.
- Palmeri ML, Wang MH, Dahl JJ, Frinkley KD, Nightingale KR. Quantifying hepatic shear modulus in vivo using acoustic radiation force. Ultrasound Med Biol 2008; 34: 546-558.
- Kwong A, Kim WR, Lake JR. OPTN/SRTR 2018 Annual Data Report: Liver. Am J Transplant; 20: 193-299.
- Younossi Z, Stepanova M, Ong JP. Non-alcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates. Clin Gastroenterol Hepatol 2019; 17: 748-55. e3.
- Jennison E, Patel J, Scorletti E, Byrne CD. Diagnosis and management of non-alcoholic fatty liver disease. Postgrad Med J 2019; 95: 314-322.
- Berger D, Desai V, Janardhan S. Con: Liver biopsy remains the gold standard to evaluate fibrosis in patients with non-alcoholic fatty liver disease. Clin Liver Dis (Hoboken) 2019; 13: 114-116.
- Papatheodoridi M, Cholongitas E. Diagnosis of non-alcoholic fatty liver disease (NAFLD): current concepts. Curr Pharm Des 2018; 24: 4574-4586.
- Watanabe S, Hashimoto E, Ikejima K. Evidence-based clinical practice guidelines for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis. J Gastroenterol 2015; 50: 364-377.
- Castera L, Winnock M, Pambrun E. Comparison of transient elastography (FibroScan), FibroTest, APRI and two algorithms combining these non?invasive tests for liver fibrosis staging in HIV/HCV coinfected patients: ANRS CO13 HEPAVIH and FIBROSTIC collaboration. HIV Med 2014; 15: 30-39.
- Joo SK, Kim W, Kim D, Kim JH. Steatosis severity affects the diagnostic performances of noninvasive fibrosis tests in non-alcoholic fatty liver disease. Liver Int 2018; 38: 331-341.
- Sande JA, Verjee S, Vinayak S, Amersi F, Ghesani M. Ultrasound shear wave elastography and liver fibrosis: A Prospective Multicenter Study. World J Hepatol 2017; 9: 38-47.
- Lee J, Vali Y, Boursier J. Prognostic accuracy of FIB?4, NAFLD fibrosis score and APRI for NAFLD?related events: a systematic review. Liver Int 2021; 41: 261-270.
- McPherson S, Stewart SF, Henderson E, Burt AD, Day CP, et al. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut 2010; 59: 1265-1269.
- Demir M, Lang S, Nierhoff D. Stepwise combination of simple noninvasive fibrosis scoring systems increases diagnostic accuracy in non-alcoholic fatty liver disease. J Clin Gastroenterol 2013; 47: 719-726.
- Sun W, Cui H, Li N. Comparison of FIB?4 index, NAFLD fibrosis score and BARD score for prediction of advanced fibrosis in adult patients with non?alcoholic fatty liver disease: a meta?analysis study. Hepatol Res 2016; 46: 862-870.
- Vilar-Gomez E, Chalasani N. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers. J Hepatol 2018; 68: 305-315.
- Angulo P, Hui JM, Marchesini G. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45: 846-854.
- Treeprasertsuk S, Björnsson E, Enders F, Suwanwalaikorn S, Lindor KD. NAFLD fibrosis score: a prognostic predictor for mortality and liver complications among NAFLD patients. World J Gastroenterol 2013; 19: 1219.
- Lombardi R, Airaghi L, Targher G. NAFLD fibrosis score (NFS) can be used in outpatient services to identify chronic vascular complications besides advanced liver fibrosis in type 2 diabetes. J Diabetes Complications 2020; 34: 107684.
- Schmitz MT, Kroh A, Ulmer TF. Evaluation of NAFLD and fibrosis in obese patients–a comparison of histological and clinical scoring systems. BMC gastroenterol 2020; 20: 1-9.
- Ito T, Nguyen VH, Tanaka T. Poor diagnostic efficacy of noninvasive tests for advanced fibrosis in obese or younger than 60 diabetic NAFLD patients. Clin Gastroenterol Hepatol 2022.
- Tan EX, Lee JW-J, Jumat NH. non-obese non-alcoholic fatty liver disease (NAFLD) in Asia: an international registry study. Metabolism 2022; 126: 154911.
- Petta S, Wong VS, Cammà C. Serial combination of non?invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with NAFLD. Aliment Pharmacol Ther 2017; 46: 617-627.
- Aubé C, Oberti F, Korali N. Ultrasonographic diagnosis of hepatic fibrosis or cirrhosis. J Hepatol 1999; 30: 472-478.
- Friedrich-Rust M, Wunder K, Kriener S. Liver fibrosis in viral hepatitis: noninvasive assessment with acoustic radiation force impulse imaging versus transient elastography. Radiology 2009; 252: 595-604.
- Wong VWS, Vergniol J, Wong GLH. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in non-alcoholic fatty liver disease. Hepatology 2010; 51: 454-462.
- Karlas T, Petroff D, Garnov N. Non-invasive assessment of hepatic steatosis in patients with NAFLD using controlled attenuation parameter and 1H-MR spectroscopy. PloS One 2014; 9: e91987.
- Lup?or M, Badea R, Stef?nescu H. Performance of unidimensional transient elastography in staging non-alcoholic steatohepatitis. J Gastrointestin Liver Dis 2010; 19: 53-60.
- Myers RP, Pomier?Layrargues G, Kirsch R. Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients. Hepatology 2012; 55: 199-208.
- Yoneda M, Mawatari H, Fujita K. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with non-alcoholic fatty liver disease (NAFLD). Digestive and Liver Disease 2008; 40: 371-378.
- Sasso M, Beaugrand M, de Ledinghen V. Controlled attenuation parameter (CAP): a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol 2010; 36: 1825-1835.
- Sasso M, Tengher-Barna I, Ziol M. Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan®: validation in chronic hepatitis C. J Viral Hepat 2012; 19: 244-253.
- Chon YE, Jung KS, Kim SU. Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases: a prospective study of a native Korean population. Liver Int 2014; 34: 102-109.
- de Lédinghen V, Wong GL, Vergniol J. Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2016; 31: 848-855.
- Karlas T, Petroff D, Sasso M. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol 2017; 66: 1022-1030.
- Siddiqui MS, Vuppalanchi R, Van Natta ML. Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with non-alcoholic fatty liver disease. Clin Gastroenterol Hepatol 2019; 17: 156-163.e2.
- Friedrich-Rust M, Romen D, Vermehren J. Acoustic radiation force impulse-imaging and transient elastography for non-invasive assessment of liver fibrosis and steatosis in NAFLD. Eur J Radiol 2012; 81: e325-31.
- D'Onofrio M, Crosara S, De Robertis R. Acoustic radiation force impulse of the liver. World J Gastroenterol 2013; 19: 4841-4849.
- Fierbinteanu Braticevici C, Sporea I, Panaitescu E, Tribus L, et al. Value of acoustic radiation force impulse imaging elastography for non-invasive evaluation of patients with non-alcoholic fatty liver disease. Ultrasound Med Biol 2013; 39: 1942-1950.
- Friedrich?Rust M, Nierhoff J, Lupsor M. Performance of acoustic radiation force impulse imaging for the staging of liver fibrosis: a pooled meta?analysis. J Viral Hepat 2012; 19: e212-e219.
- Palmeri ML, Wang MH, Rouze NC. Noninvasive evaluation of hepatic fibrosis using acoustic radiation force-based shear stiffness in patients with non-alcoholic fatty liver disease. J Hepatol 2011; 55: 666-672.
- Yoneda M, Suzuki K, Kato S. Non-alcoholic fatty liver disease: US-based acoustic radiation force impulse elastography. Radiology 2010; 256: 640-647.
- Ebinuma H, Saito H, Komuta M. Evaluation of liver fibrosis by transient elastography using acoustic radiation force impulse: comparison with Fibroscan®. J Gastroenterol 2011; 46: 1238-1248.
- Boursier J, Isselin G, Fouchard-Hubert I. Acoustic radiation force impulse: a new ultrasonographic technology for the widespread noninvasive diagnosis of liver fibrosis. Eur J Gastroenterol Hepatol 2010; 22: 1074-1084.
- Kotronen A, Peltonen M, Hakkarainen A. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology 2009; 137: 865-872.
- Musso G, Gambino R, Durazzo M, Cassader M. Noninvasive assessment of liver disease severity with liver fat score and CK-18 in NAFLD: Prognostic value of liver fat equation goes beyond hepatic fat estimation. Hepatology 2010; 51: 715-717
- Hyysalo J, Männistö VT, Zhou Y. A population-based study on the prevalence of NASH using scores validated against liver histology. J Hepatol 2014; 60: 839-846.
- Poynard T, Lebray P, Ingiliz P. Research article Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest). BMC Gastroenterol 2010; 10: 40.